|Videos|December 29, 2020

Metastatic Castrate-Resistant Prostate Cancer

Author(s)Kristie L. Kahl

Episodes in this series

EP. 1 PSMA in Prostate Cancer

EP. 1 PSMA in Prostate Cancer

EP. 2 Metastatic Castrate-Resistant Prostate Cancer

EP. 2 Metastatic Castrate-Resistant Prostate Cancer

EP. 3 PARP Inhibitors and Immunotherapy in Prostate Cancer

EP. 3 PARP Inhibitors and Immunotherapy in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

PSMA-targeted CD28 bispecific enters phase 1 trial in mCRPC

ByHannah Clarke

September 14th 2026

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

ByLorelei A. Mucci, ScD, MPH

September 11th 2026

Doublet or triplet? Urologists weighs in on mCSPC options

ByUrology Times staff

September 10th 2026

Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD

ByMartin Schoen, MD, PhD,Hannah Clarke

September 10th 2026

App-based intervention aims to increase PSA screening among Black men

ByHannah Clarke

September 9th 2026

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Managing BPH Before Prostate Radiotherapy: Options Compared

Patient Selection and Partnership in Prostate Radiotherapy Spacing

Andrew Peterson, MD, discusses advances in artificial urinary sphincter technology

Cameron Jones, MD, discusses patient selection for Aquablation

PSMA-targeted CD28 bispecific enters phase 1 trial in mCRPC